Achillion Pharmaceuticals, Inc. Nominates ACH-3422 as Nucleotide for the Treatment of Chronic HCV

Published: May 30, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW HAVEN, Conn., May 30, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the nomination of the preclinical compound, ACH-3422, a novel small molecule nucleotide prodrug of a uridine analog designed to inhibit HCV NS5B polymerase. This compound will be advanced as a development candidate for the treatment of chronic hepatitis C (HCV) viral infection. Achillion plans to complete regulatory submissions during the first quarter of 2014, with first-in-human studies anticipated in the first half of 2014, followed by combination development in the second half of 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news